AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amgen Inc. (AMGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite strong financial performance and promising growth trends, the technical indicators and recent price action suggest caution. The stock is experiencing a downward trend, and insider selling is significantly high. While the options data indicates a relatively neutral sentiment, the lack of strong positive catalysts and mixed analyst ratings make it prudent to hold off on buying for now.
The MACD is negatively expanding (-1.962), indicating bearish momentum. RSI is at 34.061, which is neutral but approaching oversold territory. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below key pivot support levels (S1: 366.089). Overall, the technical indicators suggest a bearish short-term trend.
Amgen's Q4 financials showed strong growth, with revenue up 8.58% YoY, net income up 112.60% YoY, and EPS up 112.07% YoY. The gross margin also increased to 72.88%. Analysts have raised price targets recently, reflecting optimism about the company's long-term pipeline and growth potential.
The stock has recently declined by 3.08% in regular trading and 0.23% in post-market trading. Insider selling has increased by 475.47% over the last month, which could indicate a lack of confidence from management. Additionally, the MACD and RSI suggest bearish momentum, and the stock is trading below key support levels. Analyst ratings are mixed, with some firms downgrading the stock or maintaining neutral ratings.
Amgen reported strong Q4 2025 financials with revenue of $9.87 billion, up 8.58% YoY. Net income increased significantly by 112.60% YoY to $1.33 billion, and EPS rose by 112.07% YoY to $2.46. Gross margin improved to 72.88%, up 10.84% YoY, reflecting robust operational efficiency.
Analyst ratings are mixed. Piper Sandler raised the price target to $432 with an Overweight rating, while Freedom Capital downgraded the stock to Hold with a $375 price target. Other analysts have raised price targets but maintained neutral or equal weight ratings. The consensus reflects cautious optimism but highlights concerns about loss of exclusivity and fair valuation.
